Sylvia Hristakeva
@hristakeva.bsky.social
150 followers 88 following 8 posts
Assistant Professor @Cornell. Econ and Quant Marketing.
Posts Media Videos Starter Packs
This matters for policy as the indirect effects may undermine the goals of targeted pricing policies. What appears to be a simple price cut can reshape how drugs are promoted and the information available to physicians.
We provide empirical evidence that pharmaceutical firms respond strategically. They reduce promotional payments to physicians for drugs facing the largest discounts and increase promotion for others that remain more profitable.
The 340b program requires drug manufacturers to grant steep discounts on drugs to qualifying hospitals. The design of the program causes discounts to vary across drugs, creating incentives for firms to reallocate promotional efforts across their drugs rather than uniformly reduce
Governments often regulate prices (e.g., capping drug prices or taxing unhealthy goods) to achieve policy goals. But what happens when firms respond strategically? In our new Management Science paper, we study how pharma firms adjust promotions under the 340b Program.
In my Marketing Science paper, I further show that smaller retailers are more likely to distort assortments to gain leverage in contract negotiations. Without scale, assortment control is a key tool for securing preferential contracts from suppliers.
Link to paper: 
papers.ssrn.com/sol3/papers....
Determinants of Channel Profitability: Retailers' Control over Product Selections as Contracting Leverage
Retailers control what products are offered on shelves, which may allow them to capture preferential contracts from their suppliers. I analyze the determinants
papers.ssrn.com
The FTC's case against PepsiCo highlights how promotional payments can give big-box retailers an unfair advantage. My research shows that side payments are just as important as wholesale price discounts in supplier negotiations. #FTC #EconSky
Thrilled to be working with @jurawho.bsky.social and @leofeler.com on such an important topic! The paper documents how purchasing patterns change with adoption of GLP-1 medications, exploring changes across key dimensions like motivation, age, and income.
jurawho.bsky.social
🚨Closing out 2024 with a new paper with @hristakeva.bsky.social and @leofeler.com: How GLP-1 medications like Ozempic are reshaping food demand and changing the rules of the game for the food industry.
Screenshot of paper title and abstract